Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Cristina del Peso Gilsanz"'
Publikováno v:
Endocrinologia, Diabetes Y Nutricion
Publikováno v:
Endocrinologia, Diabetes Y Nutricion
Endocrinología, Diabetes y Nutrición
Endocrinología, Diabetes y Nutrición
Autor:
Noelia Victoria García-Talavera Espín, Carles Iniesta Navalón, Cristina del Peso Gilsanz, Sup> Bienvenida Gomez Sanchez, Maria Teresa Gallego Garcia, Amparo Meoro Aviles, Maria Amparo Egea Valera, Lorena Rentero Redondo, Lucia Vera Pacheco
Publikováno v:
Endocrine Abstracts.
Autor:
Ricardo Soriano Sánchez, Alfonso López Ruiz, M. Ángeles Núñez Sánchez, Noelia Victoria García-Talavera Espín, Amparo Meoro Avilés, María Teresa Gallego García, Cristina del Peso Gilsanz, José Soriano Palao, Collaborative Groups of the Diabetes Obesity Unit of the Hospital Reina Sofía
Publikováno v:
Pharmacology & Pharmacy. :419-424
Adolescent obesity is a health problem worldwide. Drug therapy for obesity in children is only acceptable if done within the framework of a comprehensive weight loss, prevention of comorbidities, including health education, changes in lifestyles, die
Autor:
Alfonso López Ruiz, María Ángeles Núñez Sánchez, Noelia Victoria García-Talavera Espín, Amparo Meoro Avilés, Cristina del Peso Gilsanz, Ricardo Soriano Sánchez, María Teresa Gallego García, José Soriano Palao, María Dolores Ortuño, Sacramento Tomás Navarro, Collaborative Groups of the Diabetes and Obesity Unit of the Hospital Reina Sofía
Publikováno v:
Pharmacology & Pharmacy. :433-443
The purpose of this study was to analyze the effects of the treatment with Exenatide joint to insulin detemir. The study was carried out with obese patients with type 2 diabetes mellitus (DM2) and deficient control, despite intensive insulin therapy
Autor:
Juan Cabezuelo, Alfonso López-Ruiz, José Soriano-Palao, Amparo Meoro-Avilés, Cristina del Peso-Gilsanz, Alberto Andreu, José L. Arias
Publikováno v:
Pharmacy World & Science. 32:559-561
Case (description) the patient is a 20 years old male smoker, who was diagnosed with type 2 diabetes mellitus in 2006. Due to the inadequate response to the previously established treatment, the pharmacotherapy was modified by introducing exenatide (